Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Liabilities (2016 - 2024)

Voyager Therapeutics' Other Non-Current Liabilities history spans 10 years, with the latest figure at $39.4 million for Q3 2024.

  • For Q3 2024, Other Non-Current Liabilities rose 108.09% year-over-year to $39.4 million; the TTM value through Sep 2024 reached $39.4 million, up 108.09%, while the annual FY2023 figure was $18.1 million, 15.03% down from the prior year.
  • Other Non-Current Liabilities for Q3 2024 was $39.4 million at Voyager Therapeutics, down from $41.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $44.4 million in Q4 2020 and bottomed at $18.1 million in Q4 2023.
  • The 5-year median for Other Non-Current Liabilities is $31.1 million (2020), against an average of $31.9 million.
  • The largest annual shift saw Other Non-Current Liabilities plummeted 46.3% in 2022 before it soared 109.51% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $44.4 million in 2020, then fell by 10.81% to $39.6 million in 2021, then crashed by 46.24% to $21.3 million in 2022, then dropped by 15.03% to $18.1 million in 2023, then soared by 117.57% to $39.4 million in 2024.
  • Per Business Quant, the three most recent readings for VYGR's Other Non-Current Liabilities are $39.4 million (Q3 2024), $41.2 million (Q2 2024), and $43.0 million (Q1 2024).